Effect of tolvaptan on the prognosis of patients with hepatic ascites

Autor: Hidemori Sakamoto, Shigeho Maenohara, Takazumi Yada, Osamu Kubozono, Seiichi Mawatari, Shuji Kanmura, Yukiko Inada, Akiko Saishoji, Takuya Hiwaki, Akio Ido, Hirofumi Uto, Yasunari Hiramine, Yasushi Imamura, Hirofumi Higashi
Rok vydání: 2019
Předmět:
Zdroj: Hepatology Research. 49:765-777
ISSN: 1872-034X
1386-6346
DOI: 10.1111/hepr.13337
Popis: AIM Despite accumulating evidence concerning the efficacy of tolvaptan in the treatment of body fluid retention or hyponatremia, the effect of tolvaptan on the prognosis of patients with hepatic ascites has not been fully investigated. METHODS A total of 628 patients with hepatic ascites who were treated with diuretics (furosemide, spironolactone, or tolvaptan) between 2007 and 2017 were enrolled and divided into two groups: those who received tolvaptan (original tolvaptan group, n = 278) and those who did not (original control group, n = 350). The cumulative survival rates between the groups were compared and the factors associated with survival in patients with hepatic ascites were identified using a Cox regression analysis. In addition, propensity score matching was applied in patients who started conventional diuretics for new-onset hepatic ascites after September 2013 (pre-matching tolvaptan group, n = 177; pre-matching control group, n = 63), and the cumulative survival rates were compared between the post-matching tolvaptan and control groups. RESULTS The survival rate was significantly higher in the tolvaptan group than the control group (P = 0.005), and tolvaptan therapy was identified as an independent factor associated with survival (hazard ratio 0.721 for death relative to control, P
Databáze: OpenAIRE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje